

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

BSE Limited 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
<b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> August 5, 2016	
<b>Re.:</b> Updates	

Dear Sir / Madam,

On 20<sup>th</sup> June 2016, the Company had announced the acquisition of two ANDAs from Teva that were being divested by Teva as a pre-condition to its acquisition of Allergan's generic business. The acquisition of these ANDAs was contingent on the closing of the Teva-Allergan Generics transaction and approval by the US Federal Trade Commission.

We wish to inform that the transaction has now been completed and these ANDAs have been acquired by its 100% subsidiary, Zydus Worldwide DMCC.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, Cadila Healthcare Limited



**Upen H. Shah**  
Company Secretary

